Therapeutic Strategies Following Endoscopic Submucosal Dissection for T1a-MM/T1b-SM1 Esophageal Squamous Cell Carcinoma: Comparisons of Long-term Outcomes with Propensity Score-matched Analysis

Overview

Journal Surg Endosc

Publisher Springer

Specialties Gastroenterology
General Surgery
Radiology

Date 2022 Oct 11

PMID 36220991

Authors

Jun Li

Luowei Wang

Xingang Shi

Jie Chen

Zhendong Jin

Duowu Zou

Zhaoshen Li

Feng Liu

Affiliations

Soon will be listed here.

Abstract

Background: For esophageal squamous cell carcinoma (ESCC) invading the muscularis mucosa (T1a-MM) or upper submucosa (T1b-SM1, up to 200 µm), the curative effectiveness of endoscopic submucosal dissection (ESD) and additional therapeutic strategies remain controversial. The present study aims to investigate the effectiveness of ESD followed by different therapeutic strategies in treating such patients.

Methods: A total of 242 patients with T1a-MM/T1b-SM1 ESCCs were involved. Data on therapeutic outcomes and long-term survivals were collected for analysis. Propensity score-matched analysis was performed to compensate for selection bias between patients with no additional therapy (NAT group) and those with additional therapy (AT group).

Results: R0 resection rate was 83.1% and curative resection rate was 78.5%. After a mean follow-up period of 57.8 ± 27.3 months, the cumulative recurrence rate was 7.9%. The 5-year overall survival (OS) and cause-specific survival (CSS) rate was 91.1% and 94.0%. In a matched cohort of 24 pairs, the 5-year OS and CSS rates showed no significant difference between NAT group (82.0% and 87.1%) and AT group (86.0% and 89.9%) (P > 0.05). In the subgroup of patients with noncurative ESD (n = 52), the 5-year OS and CSS rates were significantly higher in surgery group (90.2% and 95.2%) than that in NAT group (50.1% and 59.5%) and chemoradiotherapy group (51.4% and 60.0%) (P < 0.05).

Conclusions: ESD with no additional therapy could achieve favorable long-term outcomes in treating T1a-MM/T1b-SM1 ESCCs. For patients with noncurative ESD, surgery ranks a prime recommendation over CRT.

Citing Articles

Esophagectomy Versus Endoscopic Resection with Adjuvant Therapy for T1b/T2 Esophageal Cancer: A Systematic Review and Meta-Analysis.

Peters E, Robinson M, Patel N, Kidane B Cancers (Basel). 2025; 17(4).

PMID: 40002274 PMC: 11853579. DOI: 10.3390/cancers17040680.

References

Pennathur A, Gibson M, Jobe B, Luketich J . Oesophageal carcinoma. Lancet. 2013; 381(9864):400-12. DOI: 10.1016/S0140-6736(12)60643-6. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Muto M, Minashi K, Yano T, Saito Y, Oda I, Nonaka S . Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol. 2010; 28(9):1566-72. PMC: 2849774. DOI: 10.1200/JCO.2009.25.4680. View

Min Y, Lee H, Song B, Min B, Kim H, Choi Y . Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis. Gastrointest Endosc. 2018; 88(4):624-633. DOI: 10.1016/j.gie.2018.04.2360. View

Takahashi H, Arimura Y, Masao H, Okahara S, Tanuma T, Kodaira J . Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010; 72(2):255-64, 264.e1-2. DOI: 10.1016/j.gie.2010.02.040. View

Ishihara R, Arima M, Iizuka T, Oyama T, Katada C, Kato M . Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc. 2020; 32(4):452-493. DOI: 10.1111/den.13654. View

Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A . Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015; 47(9):829-54. DOI: 10.1055/s-0034-1392882. View

Yao J, Li J, Wang P, Liu F, Li Z . A novel technique using high energy synchronous double-wave laser in endoscopic submucosal dissection of patients with superficial esophageal neoplasm. Endoscopy. 2018; 50(12):1175-1179. DOI: 10.1055/a-0620-8403. View

Tamiya Y, Nakahara K, Kominato K, Serikawa O, Watanabe Y, Tateishi H . Pneumomediastinum is a frequent but minor complication during esophageal endoscopic submucosal dissection. Endoscopy. 2009; 42(1):8-14. DOI: 10.1055/s-0029-1215215. View

10.

Zhou G, Yuan F, Cai J, Tang X, Gong W, Su L . Efficacy of prednisone for prevention of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Thorac Cancer. 2017; 8(5):489-494. PMC: 5582460. DOI: 10.1111/1759-7714.12473. View

11.

Qi Z, Chen T, Li B, Ren Z, Yao L, Shi Q . Endoscopic submucosal dissection for early esophageal cancer in elderly patients with relative indications for endoscopic treatment. Endoscopy. 2018; 50(9):839-845. DOI: 10.1055/a-0577-2560. View

12.

Ikeda A, Hoshi N, Yoshizaki T, Fujishima Y, Ishida T, Morita Y . Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion. Intern Med. 2015; 54(22):2803-13. DOI: 10.2169/internalmedicine.54.3591. View

13.

Hamada K, Ishihara R, Yamasaki Y, Hanaoka N, Yamamoto S, Arao M . Efficacy and Safety of Endoscopic Resection Followed by Chemoradiotherapy for Superficial Esophageal Squamous Cell Carcinoma: A Retrospective Study. Clin Transl Gastroenterol. 2017; 8(8):e110. PMC: 5587838. DOI: 10.1038/ctg.2017.36. View

14.

Kudou M, Shiozaki A, Fujiwara H, Konishi H, Shoda K, Arita T . Efficacy of Additional Surgical Resection After Endoscopic Submucosal Dissection for Superficial Esophageal Cancer. Anticancer Res. 2017; 37(9):5301-5307. DOI: 10.21873/anticanres.11956. View

15.

Kawaguchi G, Sasamoto R, Abe E, Ohta A, Sato H, Tanaka K . The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015; 10:31. PMC: 4316795. DOI: 10.1186/s13014-015-0337-4. View

16.

Hisano O, Nonoshita T, Hirata H, Sasaki T, Watanabe H, Wakiyama H . Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. Radiat Oncol. 2018; 13(1):14. PMC: 5789550. DOI: 10.1186/s13014-018-0960-y. View

17.

Liu Y, Qian D, Tang B, Fan C, Yu J, Lin H . Feasibility of Endoscopic Submucosal Dissection for Early Esophageal Squamous Cell Carcinoma with Relative Indications. Dig Surg. 2020; 38(1):14-23. DOI: 10.1159/000507437. View

18.

Naito S, Yoshio T, Ishiyama A, Tsuchida T, Tokura J, Namikawa K . Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment. Dig Endosc. 2021; 34(4):793-804. DOI: 10.1111/den.14154. View

19.

Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M . Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2021; 161(6):1878-1886.e2. DOI: 10.1053/j.gastro.2021.08.007. View

20.

Sun F, Yuan P, Chen T, Hu J . Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta-analysis. J Cardiothorac Surg. 2014; 9:78. PMC: 4052291. DOI: 10.1186/1749-8090-9-78. View